Cognition Therapeutics (CGTX) Shares Outstanding (Weighted Average) (2020 - 2026)
Cognition Therapeutics (CGTX) reported Shares Outstanding (Weighted Average) of $514500.0 for Q1 2026, down 99.17% year-over-year from $61.8 million in Q1 2025, and little changed on a QoQ basis from $514500.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $514500.0 in Q1 2026.
- Quarterly Shares Outstanding (Weighted Average) fell 99.17% year-over-year to $514500.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $514500.0 (down 99.17% YoY) and the FY2025 annual result came in at $72.8 million, changed N/A from the prior year.
- Shares Outstanding (Weighted Average) was little changed at $514500.0 in Q1 2026 per CGTX's latest filing, from $514500.0 in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $62.2 million in Q2 2025 and bottomed at $514500.0 in Q3 2025.
- The 5-year median for Shares Outstanding (Weighted Average) is $29.4 million (2023), against an average of $28.7 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) surged 3976.34%; it then plunged 99.17% in 2026.
- Tracing CGTX's Shares Outstanding (Weighted Average) over 5 years: stood at $23.6 million in 2022, then advanced by 27.03% to $30.0 million in 2023, then soared by 32.31% to $39.7 million in 2024, then slumped by 98.71% to $514500.0 in 2025, then changed by 0.0% to $514500.0 in 2026.
- Per Business Quant, the three latest CGTX Shares Outstanding (Weighted Average) figures stand at $514500.0 (Q1 2026), $514500.0 (Q4 2025), and $514500.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 104.00 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 16.04 Bn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | 514,500.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 514,500.00 |
| Dec 31, 2025 | 514,500.00 |
| Sep 30, 2025 | 514,500.00 |
| Jun 30, 2025 | 62.17 Mn |
| Mar 31, 2025 | 61.83 Mn |
| Dec 31, 2024 | 39.73 Mn |
| Sep 30, 2024 | 38.08 Mn |
| Jun 30, 2024 | 40.06 Mn |
| Mar 31, 2024 | 33.74 Mn |
| Dec 31, 2023 | 30.03 Mn |
| Sep 30, 2023 | 30.37 Mn |
| Jun 30, 2023 | 29.36 Mn |
| Mar 31, 2023 | 29.09 Mn |
| Dec 31, 2022 | 23.64 Mn |
| Sep 30, 2022 | 23.02 Mn |
| Jun 30, 2022 | 22.51 Mn |
| Mar 31, 2022 | 22.43 Mn |
| Dec 31, 2021 | 5.19 Mn |
| Sep 30, 2021 | 585,320.00 |
| Jun 30, 2021 | 571,921.00 |
| Mar 31, 2021 | 550,175.00 |
| Dec 31, 2020 | 508,112.00 |
| Sep 30, 2020 | 537,315.00 |